OptimizeRx Corp. (NASDAQ:OPRX), a digital health company focused on facilitating communication between pharma companies, healthcare providers, and patients, reported a 36% year-over-year revenue growth for the second quarter of fiscal year 2024.
Despite this growth and positive cash flow from operations, the company acknowledged missing revenue expectations due to a delay in a significant DAAP deal. The deal, expected to contribute approximately $6 million, faced internal approval setbacks but is anticipated to finalize in Q3 with revenue contribution in the latter half of 2024. OptimizeRx remains committed to converting more brands to DAAP and is implementing pricing changes for more consistent revenue recognition.
Key Takeaways
- 36% year-over-year revenue growth in Q2, with $18.8 million in revenue.
- Positive cash flow from operations and a beat for adjusted EBITDA.
- Delay in a significant DAAP deal worth about $6 million, expected to be resolved in Q3.
- Strong pipeline of DAAP deals, with 50% from the DTC side.
- Second quarter net loss of $4 million, gross margin of 62.2%.
- Cash balance of $15 million and remaining debt financing of $37.3 million.
- Expectations to meet annual revenue guidance with a focus on cross-selling to DTC and HCP clients.
Company Outlook
- OptimizeRx expects to meet revenue guidance for the year.
- Plans to convert more of the 300+ supported brands to DAAP.
- Pricing mechanism changes to be rolled out for consistent revenue recognition.
- Strong focus on cross-selling to both DTC and HCP clients.
Bearish Highlights
- Revenue fell short of expectations due to the delayed DAAP deal.
- First-half performance slightly behind expectations.
Bullish Highlights
- Significant progress made in DAAP initiative.
- Material separation in revenue per client between top three and top 20 pharma clients.
- Closed the first HCP DTC cross-sell via DAAP, with more expected.
- Good integration and teamwork within the Medicx customer base.
Misses
- Delayed $6 million DAAP deal impacted expected revenue for Q2.
- Net loss reported at $4 million for the second quarter.
Q&A Highlights
- High conviction and meaningful results with the largest and longest-lasting client.
- Requests for both HCP and DTC connected activity in the sales pipeline.
- Full staffing of the sales team, with expectations to see results in the second half of the year.
- Macro environment seen as stabilizing, with little impact expected from the upcoming election.
OptimizeRx is seeing positive momentum and impact in the market with their comprehensive solutions, which leverage AI-generated models and proprietary data sets. The company's platform is designed to address various challenges in healthcare, such as brand awareness, education, affordability, and patient recruitment. With a strong pipeline and a focus on strategic cross-selling, OptimizeRx is poised to continue its growth trajectory in the evolving digital health space. The company will keep the market informed about any potential changes to their annual outlook.
InvestingPro Insights
OptimizeRx Corp. (OPRX) has demonstrated resilience with a robust revenue growth of 36% year-over-year in Q2 2024, showcasing the potential of its digital health solutions. However, to provide a more comprehensive view of the company's performance and future prospects, it's essential to consider additional insights from InvestingPro.
InvestingPro Data indicates that OptimizeRx has a market capitalization of $157.67M, reflecting its position in the market. The company's P/E ratio stands at -8.48, suggesting that investors are expecting future earnings growth, despite the company not being profitable over the last twelve months. This expectation is further supported by a significant quarterly revenue growth of 51.43% in Q1 2024. These figures highlight the company's ability to generate revenue and suggest a trajectory towards profitability.
Among the InvestingPro Tips, it's noteworthy that management at OptimizeRx has been actively buying back shares, signaling confidence in the company's value and future performance. Additionally, while net income is expected to grow this year, two analysts have revised their earnings downwards for the upcoming period, indicating a mixed outlook that investors should consider. Nevertheless, with liquid assets exceeding short-term obligations and the company operating with a moderate level of debt, OptimizeRx appears to have a solid financial foundation to support its operations and growth initiatives.
Investors looking for more in-depth analysis can find additional tips on InvestingPro, including a total of 9 tips for OptimizeRx, which can be accessed at https://www.investing.com/pro/OPRX. These tips provide a richer context for the company's financial health and strategic direction, offering valuable information for making informed investment decisions.
Full transcript - OPTIMIZERx Corp (OPRX) Q2 2024:
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx's Second Quarter Fiscal 2024 Earnings Call. With us today is the Chief Executive Officer of OptimizeRx, William Febbo. He is joined by Chief Financial Officer, Ed Stelmakh; President, Steve Silvestro; General Counsel, Marion Odense-Ford; and Senior Vice President of Corporate Finance, Andrew D'Silva. At the conclusion of today's earnings call, I will provide some important cautions regarding the forward-looking statements made by management during today's call. I would like to remind everyone that today's call is being recorded and will be made available for replay via webcast only. Instructions are included in today's press release and in the Investors section of the company's website. Now, I would like to turn the call over to OptimizeRx CEO, William Febbo. Sir, please go ahead.
William Febbo: Thank you, operator, and good afternoon to everyone joining today's second quarter 2024 earnings call. While we welcome 36% year-over-year revenue growth, positive cash flow from operations, and a beat for adjusted EBITDA, we fell short on the revenue expectations and consensus mid-point. This was primarily a result of a timing issue with one of our largest DAAP deals to-date. We are having success in converting our DAAP pipeline into closed deals. However, because DAAP is new innovative solution in the market, there are additional approvals at the pharma customer level required to closeout all the items that would allow us take the revenue into the quarter. We were working hard with our client to get everything documented, but we didn't get it there before the end of the quarter. That said, we are building momentum with our clients and partners that have embraced our DAAP solutions and proprietary network, and this is getting us closer to being pharma's preferred partner for brand marketing. As you're aware, pharma as an industry runs all new commercial tactics through internal multi-functional approvals, particularly for multimillion dollar deals, and we needed these additional approvals to close. In this particular instance, one of our longest standing clients committed to moving forward with approximately $6 million multi-brand DAAP program with that was due to launch in Q2 2024 and got slightly delayed in their internal approval process. This customer is now nearly complete with its approval process and we expect full contract approvals to be completed in Q3 with conversion to revenue in the second half of 2024. I believe we would have surpassed consensus expectations on the top as well as the bottom had this timing shift not taken place. But the great news is that we're moving forward and the size of the transaction illustrates the power of the DAAP platform. Our objective continues to remain very clear to convert as many of the over 300 brands we currently support to DAAP and since the second half of 2023, we have made significant progress with this initiative and have seen tremendous momentum with our clients who want to convert to DAAP. As the number of deals continues to grow, we have accumulated enough market pricing knowledge to establish a more consistent pricing mechanism as a way of making our revenue recognition less lumpy, stickier, and more consistent over time. We are in the process of rolling these out, these changes out in Q3 as we continue along our evolution as a strategic partner to the top pharma companies in the world. In fact, we've seen a material separation between our top three pharma clients with average revenue per client at $9.7 million versus our top 20 pharma clients with an average revenue of $2.7 million, which we believe is a testament to the value our top clients see in our solutions as they continue to award larger share of their commercial wallet to OptimizeRx. While we are dealing with the timing issue, we are not seeing pullback from our clients on their spending in the second half of the year. Supported by an amazing team and a solid technology platform, our momentum is being driven by our ability to address our clients' largest challenge to find and engage brand eligible patients seamlessly. It's not just about purchasing media, it's about precise targeting with machine learning and a compliant methodology, which is delighting our clients and yielding positive ROIs to them. We are seeing continued customer adoption as pharma is looking for partners with scalable solutions with both HCP and DTC reach, interoperability across multiple points of care and capability to accurately report insights back in a timely manner. Since the second half of 2023, we've seen accelerated success in converting the 300 plus brands that we support to DAAP. In the first half of 2024, we closed 17 DAAP deals, including eight in the second quarter, building on the 2024 deals we closed in 2023. These deals are direct pharma engagements, which generally are more sticky, enjoy a very high ROI, have a higher gross margin for our business and continue to support a higher annualized contract value of around $1 million. As we have said, tracking our ability to convert from tactical to DAAP will provide a clear view of the longer-term growth potential of this business. Of note, we closed our first cross-sell for the DTC side of the business into a DAAP program and enhanced our overall commercial team and leadership as well as approach to the second half for renewals, new launches and year-end at reallocations, not to mention all the planning for 2025 that takes place in the last four months of the year, we are ready with our best team to-date. In addition, we have dozens of DAAP deals in our pipeline and as shared previously, approximately 50% is coming from the DTC side of the business with numerous opportunities in late-stage negotiations. OptimizeRx remains a leading company with combined technologies to both create dynamic audiences and execute messaging across proprietary point-of-care network for our clients. We continue to see organic growth as the key driver of our business. The team is focused on executing against our thesis of driving more cross-selling to our DTC and HCP clients and continuing to fine tune the platform to maximize its revenue potential. Given our traditional close rate and pipeline conversion, we have over an 80% view for our revenue guidance for the year at this point and have approximately $15 million so far remaining for the second half of the year to fall within consensus current expectations. We believe this is possible. We will keep everyone up to date as we move through the year. And with that, I would like to turn the call over to our CFO, Ed Stelmakh, who will walk us through our financial details. Ed?
Ed Stelmakh: Thanks, Will, and good afternoon, everyone. The press release was issued with the financial results of our second quarter ended June 30, 2024 and a copy is available for viewing and may be downloaded from the Investor Relations section of our website and additional information can be obtained through our forthcoming 10-Q. Second quarter revenue came in at $18.8 million, an increase of 36% from the $13.8 million were recognized during the same period in 2023. Gross margin for this quarter increased from 56.6% in the quarter ended June 30, 2023, to 62.2% in the quarter ended June 30, 2024. Year-on-year gross margin expansion is tied to higher DAAP-related revenue as well as a favorable channel partner mix. Our operating expenses for the quarter ended June 30, 2024, increased by $2.7 million year-over-year, largely due to the Medicx Health acquisition. We had a net loss of $4 million or $0.22 per basic and fully diluted share for the three months ended June 30, 2024, as compared to a net loss of $4.1 million or $0.24 per basic and fully diluted share for the same three-month period in 2023. On a non-GAAP basis, our net income for the second quarter of 2024 was $0.3 million or $0.02 per fully diluted share outstanding as compared to non-GAAP net loss of $0.2 million, or $0.01 per fully diluted share outstanding in the same year ago period. Our adjusted EBITDA came in at $0.5 million gain for the second quarter of 2024, compared to a $0.8 million loss during the second quarter of 2023. Operating cash flow came in at $2.9 million for the first half of 2024, and we ended the quarter with a $15 million cash balance as compared to a $13.9 million balance on December 31, 2023. The remaining principal of our debt financing currently stands at $37.3 million. If you recall, to help fund the $84.5 million cash portion of last October's Medicx Health acquisition, the company took on a $40 million debt financing and we paid off $2.7 million of principal through the second quarter of 2024. We continue to believe we're well funded to execute against our operational goals. Now let's turn to our KPIs for second quarter of 2024. Average revenue for top 20 pharmaceutical manufacturers now stands at $2.7 million, and we work with all of the top 20 largest pharma companies in the world. Net revenue retention rate is showing improvement at 124%, up from 89% in Q2 2023. Meanwhile, revenue per FTE came in at $658,000, topping with $565,000 we posted in Q2 2023. We are encouraged by the continuing improvement in our KPIs as we move past external market challenges and return to growth and profitability as a leader in our space. And now with that, I will turn the call back over to Will. Will?
William Febbo: Hey operator, why don't we turn to Q&A? Thank you.
Operator: Thank you. [Operator Instructions]. And while we wait, we'll take our first question from Ryan Daniels from William Blair.
Ryan Daniels: Hey guys, thanks for taking the questions tonight. First one, maybe on large client that was postponed. You didn't say it directly, but I assume that's stuck in medical legal review, number one. And number two; was there anything unique about this relative to other customers or with this client in the past that caused that? And what's the level of your conviction that this will definitely start up at least by the end of the third quarter, so that you can see some revenue recognition.
William Febbo: Hey Ryan, thanks. Good question. Yes, we have complete conviction that it will start inside of Q3. The distinction here is how large it is. And obviously, that is just very telling against of scaling the DAAP solution. And not so much legal review just process review. It's as pharma gets their arms around language around machine learning and marketing its new. And that needs to be reviewed, but it's gone very well. Obviously, we wanted it to happen faster. We always do. But high conviction, very meaningful, and it's with our largest standing -- our longest lasting client, which we just -- the team just gets really excited about.
Ryan Daniels: Okay. That's very helpful color. And then if we think about the sales pipeline, maybe a few questions related to that. Any change in regards to what you're seeing with appetite for HCP versus DTC. I think the DAAP pipeline was kind of 50:50 last quarter. And then number two, I'm curious if you're also seeing more interest in bundles as you've kind of integrated the two offerings and really have brought to market the first integrated model for traditional digital deal with point-of-care marketing.
William Febbo: Yes. Steve, do you want to grab that one?
Steve Silvestro: Yes, happy to. Hey Ryan, thanks for the questions. We continue to see in the pipeline requests coming in now for opportunities to bid both on HCP and DTC connected activity. And I think that's something we're really excited about. We just participated in our third innovation platform with a top five client, where the goal of that platform, the goal of the event was innovative ways to connect HCP and DTC marketing to drive efficiency. And as you know, we had won the last couple that we were in with what we've done with DAAP. So very excited to see that go-forward. And we see that same activity level reflected in the pipeline, I think, the demand from the market is very, very clear. And I think pharma has really wrapped their head around creating efficiencies of bringing those two together. I think, what they don't know yet, and we're all sort of waiting through it together as we go is what execution might looks like at scale rather and so we'll -- we'll have more to report back on that next time we speak. But as you heard from Will's prepared comments, we've already closed the first HCP DTC cross-sell via DAAP. So we're excited to now see how that goes and performs. And as with everything that we've seen in pharma together and over the last 20 years of my career, they'll do something, test it. If it works well, they'll scale it and that's consistent with what we've seen across the Board in the business.
Ryan Daniels: Okay. And then just in regards to the overlap with Medicx, I know maybe two or three quarters ago, you indicated it was about a 20% overlap, given the integration of the asset and your sales. Can you give us an update on how that's trended so we can view what the potential upsell cross-sell opportunity is there? Thanks.
William Febbo: Yes, I'd say there's been really good movement there. Relative to the closing of brands as we've messaged, we expect a lot of that to really trigger in the second half. Because we're coming up, October would be the one-year anniversary. Everyone tells you it takes a year, even though you hope it takes a month. And we've seen just great cooperation among the team. We've seen curiosity from the client, which drives meetings and so I would say come Q3, we'll be able to sort of quantify that relative to the 20%. I can't do that today, but all signs are positive that the groups are working as a group, as a team, not as different groups, and we've done a good job with the training to make sure they feel they've got the skills and the resources to represent everything we do.
Ryan Daniels: Got it. All right. Thanks for the questions and again, I know it fell short given the timing issue, but given that it's just timing, I'll still say congrats on the strong performance and the momentum you're seeing. Thanks.
William Febbo: Thanks, Ryan.
Steve Silvestro: Thanks, Ryan.
Operator: And next, we'll go to Kyle Bauser with B. Riley Securities.
Kyle Bauser: Great. Thanks for taking my question. So just, Will, I think you mentioned in the prepared remarks that in relation to full year guidance, you've got about 80% visibility in revenues with $15 million go get. Can you maybe help put that into perspective for example, this time last year, how much incremental sales did you generate or maybe in another way, just trying to understand kind of your conviction here. Thank you.
William Febbo: Yes. So strong conviction, otherwise wouldn't say it. The last year was a little bit of an anomaly because we actually saw business turn up faster than we thought. But generally, we're between 75% and 85% at this point. So I feel good about where we are. When you're scaling a new solution inside of a business, it's always -- there's always challenges like this timing. And also, we bought a company last year, right? And we expect them to start to show some nice growth in the second half just based on some of the fine tuning we've done around the team, the messaging and the training. So good, strong conviction, not atypical of where we are, not tremendously better. Either I don't want to paint the wrong picture, but feel good about it.
Kyle Bauser: Got it. Appreciate that. That's helpful. And then maybe two more questions. First, seasonality, I know we're kind of on track for doing about 60% of total sales in the back half of the year. So any color you can provide on kind of Q3, Q4 seasonality? And then separately, you've talked about streamlining reporting and analysis to kind of engage with executives and the data analytics teams. Can you talk about improvements here and how that's kind of been paying off by either winning follow-on projects or referrals, et cetera? Thank you.
William Febbo: Sure. Let me start with that second one first and then maybe Andy can talk to the seasonality relative to the numbers. On the additional insights and automating insights and that is what we've really focused on over the last year is fine-tuning data and reporting because the industry really adopted fully what we're doing in this space at point of care. And when they do that, they want every data point they can get, which is terrific. That's how they make their decisions and it's -- and so we worked very hard to get to that point. In that process, we realized that 10 years doing something no one else has done, gets you a lot of really unique skill set and data. And as we invested in our team, the reporting team and the data stack and data management, we realized that we actually have some really interesting proprietary insights. That is -- those are early days. Right now, we're focused on getting DAAP to scale, getting DTC to grow and bring those two together as a combined value prop and probably inside of RFP season is when we'll start to talk to clients about 2025 relative to incremental insights. If it happens sooner, that would be great, but we're not counting on that. Andy, you want talk to seasonality?
Andrew D'Silva: Yes. Yes. As far as seasonality goes, roughly 25% at max, 30% of our full year revenue would be in the third quarter and the remainder fall into the fourth. So yes, it's pretty much the general cadence over the last few years.
Kyle Bauser: Got it. That’s perfect. Yes. Well, thanks for taking my questions and I'll jump back in the queue.
William Febbo: Thank you.
Operator: Next, we'll go to Max Michaelis with Lake Street Capital. Please go ahead.
Max Michaelis: Hey guys, thanks for taking my questions. If we're looking at the size of your DAAP deals in the pipeline, so the $6 million DAAP deal you mentioned this quarter, I mean have you seen a material change, I guess, the level of the size of DAAP deals going forward in the pipeline? And then, I guess, on top of that, if we look at your top 20 customer top three, you're spending $9.7 million and the average at $2.7 million. Have you seen that average creep up, I guess, going forward, do you expect that to creep up going forward with the remaining 17 pharmaceutical companies? Thanks.
William Febbo: So yes, it's interesting. I think the DAAP size is proportional to our tenure with clients, right? There's just more trust, more adoption and they were some of the early adopters. So -- and those would clearly fall in the top three. So it kind of answers both. We're seeing -- and that's why we called it out. We're seeing quite a big difference between the top three average and our top 20. And our job is pretty straightforward. Get the other 17 to do the same thing, and we're a much bigger business. So when we talk about converting our 300-plus brands to DAAP-related that is the mission. It's very straightforward. Steve, any other color you want to put on that relative to the process and how it's going?
Steve Silvestro: Yes. I would just add that the $6 million was not for one single DAAP deal, it was several deals. So with the same client, same multiple assets that is supporting inline. And then the other thing I would say is ACV continues to be either consistent or ticking up Max, and I think that was one of the questions that you asked. So it's very consistent and linear in terms of the progress that we're seeing but we're seeing an acceleration of interest. And I think that's what you're hearing the positivity in our voice because of the acceleration of interest. And as Will said, it's pretty clear. We know what we need to do. We just need to be about it, so to speak, but good questions.
Max Michaelis: Thanks, guys. That's it from me.
Operator: [Operator Instructions]. We'll next go to Stephanie Davis with Barclays.
Anna Kruszenski: Hey guys, this is Anna Kruszenski on for Stephanie. Thank you for taking our questions. I was wondering if we could talk a little more about the cross-sales into the Medicx customer base and just more on how that trended versus your expectations. And if you think you have adequate sales headcount to block and tackle all of these prospects or if there are more investments as part of your forward strategy? Thank you.
William Febbo: And Steve, do you want to grab that one?
Steve Silvestro: Yes, happy to. Thanks for the question. I think what we've seen is good integration and teamwork between the teams as far as approaching clients. We definitely are fully staffed right now, we hired several additional sales folks, which I think are reflected in the numbers that are from key competitors that Medicx had that are sort of top performing businesses in the space. So we feel really good about the talent that is on Board and working on behalf of the business. At this point, I think it really is just about focusing and we spent the first half of the year investing in getting those people on Board, making sure that we were appropriately staff trained, et cetera, I think we'll start to see the fruits of that bare in the second half. And so our confidence is very strong in the Medicx business performing well in the second half. In terms of first half performance, yes, I think we -- I think it's about where we expected it to be, maybe a little bit behind. As Will said, we all want a microwave success when we first acquire something. It's never really as easy as we think it's going to be in spite of our best efforts. So we continue to work on it. We've got great leadership on it, and we'll continue to chop the wood.
Anna Kruszenski: Got it. That's super helpful. Thank you. And then just as a quick follow-up, so last quarter, you talked about like the macro stabilizing. And just curious, given like the recent volatility in the market, is this trend still intact? Or if you have any sort of updated macro forecast to share?
William Febbo: Nothing more than we said in the prepared remarks, just that we're not seeing a pullback. The headwinds that we had a year ago are largely gone. FDA is cranking. Pharma is very focused on allocating funds to digital reach and measuring it, make suring it's scalable and effective. We have an election coming up, I think that won't largely affect pharma spending. Certainly, if we were all media only, you could argue there's sometimes a squeeze around that time, but we don't see that impacting our business.
Anna Kruszenski: Got it. Super helpful. Thanks, guys.
William Febbo: Have a good day, Anna.
Steve Silvestro: Take care.
Operator: Thank you. And I'd like to turn the call back to our speakers for any closing remarks.
William Febbo: Terrific. Thank you, operator, and thanks, everyone, for joining us today. While we needed to address the timing issue during the second quarter with our largest client buying more DAAP as a team, we're excited with the positive momentum and the impactful platform that we've built in this market. We're evolving to be a much stronger place than a year ago, and that's what motivates us as a team. Our collaboration with pharma manufacturers to reach healthcare professionals and patients is meaningful in the market, fueled by our innovative AI-generated models, proprietary data sets and a decade of point-of-care marketing. This market advantage helps us address and overcome many challenges. Today, we profound the offer -- proudly offer, sorry, a comprehensive solution that integrate various components into agile, powerful AI-enabled commercialization strategies. These strategies effectively tackle crucial issues such as brand awareness, education, affordability and the recruitment of hard defined patients. These are daily challenges for our clients, doctors and patients face in the current healthcare environment, and we're thrilled to be part of that solution. Our dedication to supporting doctors and patients and aligning on quality of care is a driving force behind our team and our culture. We look forward to connecting with everyone in the upcoming investor events and our next earnings call. We will provide updates on our annual outlook if there's any changes to our current guidance range. Thank you for your time and belief in the OptimizeRx team. Thank you. Operator?
Operator: Thank you, sir. Before we conclude today's call, I'd like to provide the company's Safe Harbor statement that includes important cautions regarding forward-looking statements made during today's call. Statements made by management during today's call may be contained forward-looking statements within the definition of Section 27A and the Securities Act of 1933 as amended and Section 21E of the Securities Act of 1934 as amended. These forward-looking statements should not be used to make investment decisions. The words anticipate, estimate, expect, possible and seeking and similar expressions identify forward-looking statements. They may speak only to the date that such statements are made. Such forward-looking statements in this call include statements regarding estimation of total addressable market size, market penetration, revenue growth, gross margin, operating expenses, profitability, cash flow, technology, investments, growth opportunities, acquisitions, upcoming announcements and the need for raising additional capital. They also include the management's expectations for the rest of the year and adoption of the company's digital health platform. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, further future events or otherwise. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying these forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effects of government regulation, competition and other material risks. Risks and uncertainties to which forward-looking statements are subject to could affect business and financial results and are included in the company's Annual Report on Form 10-K for the quarter ended December 31, 2023, subsequent quarterly reports on Form 10-Q and its other filings with the Securities and Exchange Commission. These forms and filings are available on the company's website and on the SEC website at sec.gov. Before we end today's conference, I would like to remind everyone that this call will be available for replay via webcast only starting later this evening running through for a year. Please refer to today's press release for replay instructions available via the company's website at www.optimizerx.com. Thank you for joining us today. This concludes today's conference. You may disconnect your lines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.